Melanoma News and Research

Latest Melanoma News and Research

MD Anderson experts create plan to guide women on healthy behaviors

"A woman's life changes at every decade and so does her body," says Therese Bevers, M.D., medical director of MD Anderson's Cancer Prevention Center. "And, just as a woman sets personal and work-related milestones, she also should set health goals for every stage of life."

19 Jan 2011

RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma

Genentech, a member of the Roche Group, today announced that BRIM3, a Phase III clinical study of RG7204, met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma.

19 Jan 2011

Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma

Plexxikon today announced positive data from an interim analysis of the BRIM3 trial, a large multi-center Phase 3 clinical study of PLX4032 in patients with previously untreated metastatic melanoma with the BRAF mutation. Patients treated with PLX4032 had an improved overall survival compared to patients treated with dacarbazine, the current standard of care.

19 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Time constraints, patient embarrassment prevent full-body skin cancer examinations

Time constraints, other illnesses and patient embarrassment may prevent dermatologists, internists and family practitioners from conducting full-body skin examinations, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals. However, dermatologists are significantly more likely than internists and family practitioners to conduct such screenings.

18 Jan 2011

Follow-up program for high-risk patients appears to detect melanomas at early stages

A follow-up program for patients at high risk of developing skin cancer appears to be associated with the detection of melanomas at early stages and with good prognosis, according to a report posted online today that will appear in the May print issue of Archives of Dermatology, one of the JAMA/Archives journals.

18 Jan 2011

Bathing tumor-ridden livers in chemotherapy increases survival time

Bathing tumor-ridden livers in chemotherapy increases the length of time certain cancer patients survive without progression of the disease, according to Phase III trial results being presented at the 3rd annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).

18 Jan 2011

CINJ clinical trial explores anti-malaria drug against melanoma

Building upon recent laboratory discoveries on resistance by cancer cells to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are conducting a clinical trial that further explores how to prevent that action.

14 Jan 2011

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

Researchers at the Duke Cancer Institute who have been studying prostate cancer cells for decades now think they know why PSA levels reflect cancer progression.

14 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Vical Incorporated today announced a new publication summarizing results from the company's completed trials of Allovectin-7 including systemic responses and an excellent safety profile in patients with metastatic melanoma.

11 Jan 2011

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

Nationwide Children's Hospital was awarded $11.5 million from the National Cancer Institute late last year to continue its role as one of two Biospecimen Core Resources for The Cancer Genome Atlas.

11 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Antigenics announces name change to Agenus

Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.

6 Jan 2011

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

People with melanoma, ovarian cancer, or prostate cancer now have a new resource that provides them with the same credible information their physicians use when determining treatment options. The National Comprehensive Cancer Network announces three new additions to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

6 Jan 2011

Scientists discover that skin cancer can spread to lungs through cell blocking activity

CANCER RESEARCH UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked. The research is published in Cancer Cell.

6 Jan 2011

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

King Pharmaceuticals resubmits NDA for REMOXY

King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. today announced that King has resubmitted a New Drug Application for REMOXY® to the U.S. Food and Drug Administration in response to a Complete Response letter received by Pain Therapeutics in December 2008.

28 Dec 2010

Melanoma News and Research

Latest Melanoma News and Research

MD Anderson experts create plan to guide women on healthy behaviors

RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma

Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Time constraints, patient embarrassment prevent full-body skin cancer examinations

Follow-up program for high-risk patients appears to detect melanomas at early stages

Bathing tumor-ridden livers in chemotherapy increases survival time

CINJ clinical trial explores anti-malaria drug against melanoma

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Antigenics announces name change to Agenus

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

Scientists discover that skin cancer can spread to lungs through cell blocking activity

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

King Pharmaceuticals resubmits NDA for REMOXY

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Melanoma News and Research

Latest Melanoma News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in